OSR (NASDAQ:OSRH – Get Free Report) and Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.
Institutional & Insider Ownership
55.3% of OSR shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 36.9% of OSR shares are owned by company insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares OSR and Dianthus Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| OSR | $1.81 million | 5.05 | -$27.06 million | ($0.37) | -0.70 |
| Dianthus Therapeutics | $2.04 million | 2,836.41 | -$162.34 million | ($4.15) | -25.50 |
OSR has higher earnings, but lower revenue than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than OSR, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
OSR has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500.
Profitability
This table compares OSR and Dianthus Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OSR | -593.15% | -8.36% | -6.24% |
| Dianthus Therapeutics | -10,096.95% | -22.53% | -21.55% |
Analyst Ratings
This is a breakdown of recent ratings for OSR and Dianthus Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OSR | 1 | 0 | 0 | 0 | 1.00 |
| Dianthus Therapeutics | 1 | 0 | 12 | 1 | 2.93 |
Dianthus Therapeutics has a consensus price target of $124.27, suggesting a potential upside of 17.42%. Given Dianthus Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Dianthus Therapeutics is more favorable than OSR.
Summary
OSR beats Dianthus Therapeutics on 8 of the 15 factors compared between the two stocks.
About OSR
OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Receive News & Ratings for OSR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OSR and related companies with MarketBeat.com's FREE daily email newsletter.
